Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This study will be executed according to a randomized double-blind placebo-controlled trial
with two parallel groups, treated over the period of 6 months with escitalopram or placebo.
Hypotheses: Escitalopram is more effective than placebo in the control of gastrointestinal
symptoms, in irritable bowel syndrome (IBS) patients with panic disorder. Escitalopram is
more effective than placebo in the control of psychiatric symptoms, in IBS patients with
panic disorder.